[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606784":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":30,"responsibleParty":47,"collaborators":10,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":10,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":10,"enrollmentInfo":59,"targetDuration":10,"studyType":62,"phases":10,"briefSummary":63,"conditions":64,"keywords":10,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"RenJi Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Adjuvant CDK4\u002F6 inhibitor",null,"CDK4\u002F6 inhibitors are drugs that block cell division in cancer cells. They are used with hormonal therapy for hormone receptor-positive breast cancer and may improve survival.",[13],"Drug: CDK4\u002F6 inhibitor",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","CDK4\u002F6 inhibitor","abemaciclib OR ribociclib",[9],[21],{"name":22,"affiliation":23,"role":24},"Wenjin Yin, M.D.","Renji Hospital,School of Medicine, Shanghai Jiaotong University","PRINCIPAL_INVESTIGATOR",[26],{"name":22,"role":27,"phone":28,"phoneExt":10,"email":29},"CONTACT","86(21)68385569","yinwenjin@renji.com",[31],{"facility":32,"status":33,"city":34,"state":10,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Renji Hospital, School of Medicine, Shanghai Jiaotong University","RECRUITING","Shanghai","200127","China","CN",{"type":39,"coordinates":40},"Point",[41,42],121.45806,31.22222,{"lat":42,"lon":41},[45],{"name":46,"role":27,"phone":28,"phoneExt":10,"email":29},"Wenjin Yin",{"type":48,"investigatorFullName":46,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Deputy Chief of Breast Surgery Department","100606784","adjuvant-cdk46-inhibitor-use-in-hrher2--breast-cancer-100606784",false,"NCT07180056","Adjuvant CDK4\u002F6 Inhibitor Use in HR+\u002FHER2- Breast Cancer","Efficacy and Safety of Adjuvant CDK4\u002F6 Inhibitors in Patients With Hormone Receptor-positive\u002FHuman Epidermal Growth Factor Receptor 2-negative Breast Cancer: a Real-world Study","Inclusion Criteria:\n\n* Aged ≥18 and older\n* Patients with pathologically confirmed breast cancer without distant metastasis or local recurrence\n* HR+\u002FHER2-\n* ECOG 0-3\n* Subjects meeting current guideline recommendations and planning to receive adjuvant CDK4\u002F6 inhibitors\n\nExclusion Criteria:\n\n* During pregnancy or lactation\n* Subjects that are unable to swallow tablets, or dysfunction of gastrointestinal absorption","ALL","18 Years",{"count":60,"type":61},229,"ESTIMATED","OBSERVATIONAL","To evaluate the efficacy and safety of adjuvant CDK4\u002F6 inhibitors in patients with hormone receptor-positive\u002Fhuman epidermal growth factor receptor 2-negative breast cancer.",[65],"Breast Cancer","2025-11-16",{"date":68,"type":69},"2025-11-19","ACTUAL",{"date":71,"type":69},"2025-08-28",{"date":73,"type":61},"2033-02",{"name":46,"class":6},1]